American Society of Addiction Medicine

This Week in Addiction Medicine from ASAM

American Society of Addiction Medicine

  • Lead Story: Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder

Lead Story: Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder

Tuesday 9th August 2022

Discover how COVID-19 telehealth policies affected buprenorphine treatment for opioid use disorder and more in this episode of 'This Week in Addiction Medicine from ASAM'.
6 minutes
Informative
Thought-provoking
Educational
Supportive
Engaging

About this podcast

This Week in Addiction Medicine from ASAM
Author:
American Society of Addiction Medicine
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Family Recovery from Addiction
Nutritional Pathways to Recovery
Navigating Intimate Relationships
Links:
Visit site
Rounded Button Dark
Do you want to link to this podcast?
Get the buttons here!

How COVID-19 Changed Buprenorphine Treatment for Opioid Use Disorder

The number of patients receiving buprenorphine continued to increase, but the delivery of care shifted to telehealth visits, suggesting that any reversal of COVID-19 policies must be carefully considered.
Imagine needing essential treatment for opioid use disorder and suddenly, the world shifts to telehealth. That's exactly what happened during the COVID-19 pandemic. In this episode of 'This Week in Addiction Medicine from ASAM', host Claire Rasmussen dives into a national study that explores how policy changes in March 2020 impacted buprenorphine treatment within the Veterans Health Administration.
The study reveals that while the number of patients receiving buprenorphine increased, the way care was delivered transformed drastically, moving from in-person visits to telehealth. This shift raises critical questions about what might happen if these policies are reversed. But that's not all. Rasmussen also touches on other compelling research, including trends in cannabis use disorder diagnoses, three-year retention rates for buprenorphine treatment, and strategies for addressing adolescent substance use.
Whether you're a healthcare professional, a student, or someone affected by addiction, this episode is packed with crucial insights and practical takeaways. So, if you're curious about how the pandemic has reshaped addiction medicine or want to stay updated on the latest research, tune in to this episode. It's an enlightening listen that offers a blend of professional expertise and real-world implications.
alcoholfree.com
Published by The Mindful Drinking Company Limited
4 Providence Court, Pynes Hill, Exeter, Devon, EX2 5JL, England
Registered in England and Wales.
Company Number: 1195057. Vat Number: GB320915135.
Registered address as above.
© Copyright 2005-2025 The Mindful Drinking Company Limited.
All Rights Reserved.
alcoholfree.com is a participant in the Amazon Associates Programme, an affiliate advertising programme designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.co.uk. As an Amazon Associate, we earn from qualifying purchases.